登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H27N5O2
化学文摘社编号:
分子量:
369.46
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
Cilostazol, United States Pharmacopeia (USP) Reference Standard
InChI key
RRGUKTPIGVIEKM-UHFFFAOYSA-N
SMILES string
O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1
InChI
1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
grade
pharmaceutical primary standard
API family
cilostazol
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PDE3A(5139)
正在寻找类似产品? 访问 产品对比指南
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Cilostazol USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monograph such as Cilostazol Tablets
General description
Cilostazol is a potent cyclic nucleotide phosphodiesterase inhibitor. It is mainly used as antiplatelet agent.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Deng-Feng Geng et al.
Cardiology, 122(3), 148-157 (2012-07-27)
Uncertainties still remain in terms of what kinds of patients benefit most from cilostazol-based triple antiplatelet therapy (TAT) after coronary stenting. We performed a meta-analysis of all relevant randomized controlled trials (RCTs) to investigate the effect of TAT versus dual
Jae-Sik Jang et al.
Cardiology, 122(3), 133-143 (2012-07-27)
To evaluate the impact of cilostazol on the angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention (PCI) with stents and treated with aspirin and thienopyridine. A total of 11 randomized controlled trials including 8,525 patients comparing triple antiplatelet
S Takahashi et al.
Journal of cardiovascular pharmacology, 20(6), 900-906 (1992-12-01)
Cilostazol, a cyclic AMP phosphodiesterase inhibitor, has been used as an antiplatelet agent. In the present study, we investigated the in vitro effect of cilostazol on DNA synthesis in rat aortic arterial smooth muscle cells (SMCs) in culture stimulated with
Courtney J Warner et al.
Journal of vascular surgery, 59(6), 1607-1614 (2014-01-29)
Although cilostazol is commonly used as an adjunct after peripheral vascular interventions, its efficacy remains uncertain. We assessed the effect of cilostazol on outcomes after peripheral vascular interventions using meta-analytic techniques. We searched MEDLINE (1946-2012), Cochrane CENTRAL (1996-2012), and trial
Kelly C Rogers et al.
The Annals of pharmacotherapy, 46(6), 839-850 (2012-06-07)
To evaluate the addition of cilostazol to standard dual antiplatelet therapy (DAT) with aspirin and clopidogrel in patients receiving coronary stenting. Relevant information was identified through a search of MEDLINE (1966-November 2011), International Pharmaceutical Abstracts (1960-2011), and Cochrane Databases (publications
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持